JB Chemicals Q2 Profit Rises 19% on Strong Domestic Demand

JB Chemicals & Pharmaceuticals Ltd (JBCH.NS) reported a strong 19% year-on-year rise in consolidated net profit for the September quarter, supported by robust demand in the domestic market. The maker of the Rantac antacid posted a profit of ₹2.08 billion ($23.7 million), up from ₹1.75 billion in the same period last year. Overall revenue increased 8% to ₹10.85 billion during the quarter, with CEO Nikhil Chopra attributing the growth to consistent outperformance by all major domestic brands.

The company’s domestic business continued to lead its performance, registering a 9% rise in revenue, while its international business grew by 7%. According to data from clinical research firm IQVIA, JB Chemicals grew 12% in the Indian pharmaceutical market, outpacing the sector’s overall growth rate of 8% for the period. The company has been steadily strengthening its brand portfolio and expanding its market share through consistent innovation and strategic focus on high-demand therapeutic areas.

Among peers, JB Chemicals trades at a forward price-to-earnings ratio of 32.48, compared with 24.54 for Glenmark Pharmaceuticals and 46.93 for Torrent Pharmaceuticals. Analysts maintain a consensus “Buy” rating on the stock, supported by strong fundamentals and double-digit profit growth expectations. JB Chemicals’ continued domestic momentum positions it as one of the top performers in India’s pharmaceutical landscape for FY25.

Pic Courtesy: google/ images are subject to copyright